Full video transcriptClick to expand
Auto-generated transcript of @_hunsky_'s video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00This is absolutely insane. More info on Reda has dropped. This is probably the craziest thing yet.
- 0:07They are saying, and I've personally seen this with people, your fertility skyrockets on Reda,
- 0:14a girl who could never get pregnant. Like they thought she was infertile. Boom. Now she's pregnant.
- 0:20I know another girl who was on birth control. They weren't trying to have a kid. And all of a sudden
- 0:29she got pregnant. Insane. I will say this though. Out of what I've been told from people,
- 0:37out of four girls who got pregnant, three of them didn't get very far in their pregnancy if you know
- 0:43what I mean. So, but they also didn't know they were pregnant and they were going out and stuff. So,
- 0:50keep that in mind. But regardless of what happens after the fact, it's looking like fertility skyrockets
- 0:57on this stuff. And I think it could be another form of potential medication in the future
- 1:04to help women who have a problem getting fertilized have kids. And this stuff really is just just
- 1:10increasing. I mean, obviously this is still in research trials, especially when it comes to
- 1:16effects outside of just fat loss and weight loss. But I'm just blown away at how much this stuff is
- 1:23covering and how good it is for the human body.
Peptides and female fertility: what TikTok gets wrong
Quick answer
The creator references anecdotal pregnancy outcomes in women apparently using retatrutide, an investigational triple agonist (GLP-1, GIP, glucagon) currently in Phase 3 trials, none of which are studying fertility as a primary endpoint. Three of four reported pregnancies ended in early loss, a safety signal the creator minimized. No peer-reviewed data exists on retatrutide's effects on conception, early pregnancy, or contraceptive drug interactions.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 7 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Peptides and female fertility: what TikTok gets wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Triple-Hormone-Receptor Agonist Retatrutide for Obesity, A Phase 2 Trial
Primary human trial source for retatrutide obesity efficacy and safety discussions.
PubMed
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease
Used when retatrutide pages touch liver-fat, MASLD, and metabolic outcomes.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Peptides and female fertility: what TikTok gets wrong should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Peptides and female fertility: what TikTok gets wrong" from _hunsky_. We read the clip as a Peptide social video fact-checks claim about Peptide social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator references anecdotal pregnancy outcomes in women apparently using retatrutide, an investigational triple agonist (GLP-1, GIP, glucagon) currently in Phase 3 trials, none of which are studying fertility as a primary endpoint.
The reason this review is not generic is the source wording and the canonical claim label "peptides women thinking about peptides need to hear this info fertili." In this clip, the useful excerpt is: "This is absolutely insane." That wording changes the review because it points to Peptide social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference (2025), Discontinuing glucagon-like peptide-1 receptor agonists and body habitus (2025), and Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition (2025), plus the creator's own wording. Peptide social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator references anecdotal pregnancy outcomes in women apparently using retatrutide, an investigational triple agonist (GLP-1, GIP, glucagon) currently in Phase 3 trials, none of which are studying fertility as a primary endpoint.
FormBlends verdict
Peptide social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator references anecdotal pregnancy outcomes in women apparently using retatrutide, an investigational triple agonist (GLP-1, GIP, glucagon) currently in Phase 3 trials, none of which are studying fertility as a primary endpoint. Three of four reported pregnancies ended in early loss, a safety signal the creator minimized. No peer-reviewed data exists on retatrutide's effects on conception, early pregnancy, or contraceptive drug interactions.
- Retatrutide is not FDA-approved for any indication and is not legally available as a prescribed fertility treatment in the United States as of 2024.
- GLP-1 receptor agonists can improve ovulatory function in women with PCOS by reducing insulin resistance and body weight, but this is an indirect effect, not direct fertility enhancement (Elkind-Hirsch et al., 2022, JCEM).
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Retatrutide is not FDA-approved for any indication and is not legally available as a prescribed fertility treatment in the United States as of 2024.
- GLP-1 receptor agonists can improve ovulatory function in women with PCOS by reducing insulin resistance and body weight, but this is an indirect effect, not direct fertility enhancement (Elkind-Hirsch et al., 2022, JCEM).
- GLP-1-class drugs may reduce oral contraceptive absorption by slowing gastric emptying, a real interaction risk that should be discussed with a prescribing physician, not interpreted as proof of fertility effects.
- The creator's own anecdote describes a 75 percent early pregnancy loss rate across four cases. That is not a footnote, it is the most clinically significant piece of information in the video.
- No published peer-reviewed study has examined retatrutide's effects on conception, early fetal development, or pregnancy outcomes. Any fertility claim about this drug is currently without scientific support.
- Anyone who is pregnant, trying to conceive, or using hormonal contraception should consult a reproductive endocrinologist or OB-GYN before using any investigational peptide or GLP-1-class compound.
- Viral anecdotes about four women do not constitute clinical evidence. Phase 3 trial enrollment for retatrutide does not include fertility as a measured endpoint.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @_hunsky_ actually say?
The creator claims a peptide called "Reda" causes fertility to "skyrocket," citing personal anecdotes: one woman who supposedly couldn't get pregnant suddenly did, another got pregnant while on birth control. He then buries a significant caveat near the end, noting that three of four women who got pregnant "didn't get very far," which is a roundabout way of describing pregnancy loss. He frames this as exciting news rather than a serious safety signal.
There is a real problem here before we even get to the science. The creator never clearly identifies what "Reda" actually is. Context clues and community usage suggest this may refer to retatrutide, a triple agonist drug targeting GLP-1, GIP, and glucagon receptors, which is currently in Phase 3 clinical trials. It is not a peptide therapy in the traditional compounding sense. It is an investigational pharmaceutical, and it is not approved by the FDA for any indication.
Does the science back this up?
No published clinical trial data supports the claim that retatrutide or any similar triple agonist dramatically boosts human fertility. There is simply no peer-reviewed evidence for this specific claim, which makes the "skyrockets" framing irresponsible.
What we do know is more nuanced. GLP-1 receptor agonists like semaglutide have shown some indirect fertility benefits in women with polycystic ovary syndrome, likely because weight loss and improved insulin sensitivity can restore ovulatory function. Elkind-Hirsch et al. (2022, Journal of Clinical Endocrinology and Metabolism) documented improved reproductive outcomes in PCOS patients on GLP-1 therapy, but this is not the same as a direct fertility enhancement effect. Extrapolating that to retatrutide's triple-agonist mechanism, and then claiming any pregnancy near the drug is caused by it, is a logical leap with no scientific foundation.
The birth control failure story is especially poorly handled. No pharmacokinetic data has been published showing retatrutide interferes with oral contraceptives, though GLP-1 agonists can theoretically affect drug absorption due to delayed gastric emptying. That is a documented interaction worth discussing carefully, not as a fertility miracle story.
What did they get wrong (or right)?
The creator got one thing directionally correct: GLP-1-class drugs are being studied for reproductive health, and weight loss through this drug class can improve fertility in people with obesity-related hormonal disruption. Credit where it is due.
But almost everything else is a problem. Three out of four anecdotal pregnancies ending in loss is not a side note, it is the headline. Describing that stat in passing, then pivoting back to how "blown away" he is, does a disservice to anyone listening. Pregnancy loss is not a minor footnote to fertility optimization content.
The claim that a woman on birth control got pregnant because of the drug, presented as proof of efficacy rather than a contraceptive interaction risk, is genuinely dangerous framing. Women on hormonal contraception who are also taking GLP-1 or similar agents should be talking to a physician, not drawing conclusions from a TikTok anecdote.
Calling retatrutide "just increasing" and "good for the human body" while acknowledging it is still in research trials in the same breath is contradictory. Phase 3 trial status means we do not know the long-term safety profile. Full stop.
What should you actually know?
If you are considering any GLP-1-class or investigational peptide drug and you want to become pregnant, or want to avoid becoming pregnant, this video should not be your information source. Talk to an OB-GYN or reproductive endocrinologist.
Here is what the evidence actually supports. Weight loss through any mechanism, including GLP-1 receptor agonism, can improve ovulatory function in women with PCOS or obesity-related anovulation. This is real, documented, and worth knowing. But it is not the same as a drug directly causing fertility to "skyrocket."
Retatrutide is not approved, not commercially available, and not legally prescribable for fertility or any other indication in the United States as of 2024. Anyone selling it as a fertility treatment is operating outside regulatory boundaries. The creator does not address this at all.
The pregnancy loss rate in this anecdote, 75 percent, is alarming enough that it should be the core of any responsible discussion about this drug and pregnancy, not an afterthought. Until clinical data exists on reproductive outcomes, the only honest position is that we do not know what this drug does to a developing pregnancy.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
_hunsky_ · TikTok creator
1.0M views on this video
Women thinking about peptides need to hear this #info #fertility
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about retatrutide?
Retatrutide is not FDA-approved for any indication and is not legally available as a prescribed fertility treatment in the United States as of 2024.
What does the video say about glp-1 receptor agonists can improve ovulatory function in women with?
GLP-1 receptor agonists can improve ovulatory function in women with PCOS by reducing insulin resistance and body weight, but this is an indirect effect, not direct fertility enhancement (Elkind-Hirsch et al., 2022, JCEM).
What does the video say about glp-1-class drugs may reduce?
GLP-1-class drugs may reduce oral contraceptive absorption by slowing gastric emptying, a real interaction risk that should be discussed with a prescribing physician, not interpreted as proof of fertility effects.
What does the video say about the creator's own anecdote describes a 75 percent early pregnancy?
The creator's own anecdote describes a 75 percent early pregnancy loss rate across four cases. That is not a footnote, it is the most clinically significant piece of information in the video.
What does the video say about no published peer-reviewed study has examined retatrutide's effects on conception,?
No published peer-reviewed study has examined retatrutide's effects on conception, early fetal development, or pregnancy outcomes. Any fertility claim about this drug is currently without scientific support.
What does the video say about anyone who?
Anyone who is pregnant, trying to conceive, or using hormonal contraception should consult a reproductive endocrinologist or OB-GYN before using any investigational peptide or GLP-1-class compound.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by _hunsky_, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.